Fundraising FoxGensight Biologics S.A
Paris, FR · Founded 2012 · France corporation · 3 known investors
Find your way into Gensight Biologics S.A
Sign up to see every warm intro you have to Gensight Biologics S.A
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Gensight Biologics S.A team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
GenSight Biologics develops clinical-stage gene therapy treatments, with a lead candidate (GS010/LUMEVOQ) in development for rare genetic diseases. The company is pursuing regulatory approval and early access programs in Europe.
Founders & leadership
Gensight Biologics S.A was founded in 2012 by Bernard Gilly.
Board
Investors · 3
How we know: Sofinnova Partners's portfolio page · Not right? Tell us
How we know: a partner's Signal profile · board seat on SEC Form D · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$25M disclosed across 1 round · 2015
▶$25MraisedJul 2015 · 15 investors · BiotechnologyRule 506(b)
- Jean-Philippe CombalExecutive Officer
- Michael Stephen WyzgaDirector
- Thomas GidoinExecutive Officer
- Didier PruneauExecutive Officer
- Florent GrosDirector
- Nitza ThomassonExecutive Officer
- Bernard GillyExecutive Officer, Director
- Guido MagniDirector
- Peter GoodfellowDirector
- Genghis Lloyd-HarrisDirector
- Offering amount
- $25M
- Amount sold
- $25M
- Sales commissions
- $1.3M
- Placement agents
- Leerink Partners LLC
- First sale
- Jul 2015
- Incorporated
- Corporation, France, 2012
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Gensight Biologics S.A do?
- GenSight Biologics develops clinical-stage gene therapy treatments, with a lead candidate (GS010/LUMEVOQ) in development for rare genetic diseases. The company is pursuing regulatory approval and early access programs in Europe.
- Who founded Gensight Biologics S.A?
- Gensight Biologics S.A was founded by Bernard Gilly in 2012.
- Who are Gensight Biologics S.A's investors?
- Gensight Biologics S.A's investors include Agoranov, Sofinnova Partners, Abingworth.
- How much funding has Gensight Biologics S.A raised?
- Gensight Biologics S.A has disclosed $25M raised across 1 round.
- Where is Gensight Biologics S.A headquartered?
- Gensight Biologics S.A is headquartered in Paris, FR.